The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study-Reference-Cited by-同舟云学术

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study

Published:2015-10-16 Issue:1 Volume:108 Page:djv301
ISSN:0027-8874
Container-title:Journal of the National Cancer Institute
language:en
Short-container-title:JNCI.J

Author:

Goldhar Hart A.,Yan Andrew T.,Ko Dennis T.,Earle Craig C.,Tomlinson George A.,Trudeau Maureen E.,Krahn Murray D.,Krzyzanowska Monika K.,Pal Raveen S.,Brezden-Masley Christine,Gavura Scott,Lien Kelly,Chan Kelvin K. W.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/108/1/djv301/17986325/djv301.pdf

Reference42 articles.

1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

3. Adjuvant targeted therapy in early breast cancer;Mackey;Cancer,2009

4. Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials

5. Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors;Journal of Clinical Oncology;2024-06-04

2. Long-term cardiovascular disease risk after anthracycline and trastuzumab treatments in US breast cancer survivors;JNCI: Journal of the National Cancer Institute;2024-05-08

3. Cancer survivor late-effects, chronic health problems after cancer treatment: what’s the evidence from population and registry data and where are the gaps?;Current Opinion in Supportive & Palliative Care;2024-03

4. HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review;Journal of Cardiovascular Development and Disease;2023-12-06

5. Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer;Journal of Clinical Medicine;2023-10-24